AN2 Therapeutics (ANTX) Shares Outstanding (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Shares Outstanding (Entity) for 6 consecutive years, with $36.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 19.39% year-over-year to $36.0 million; the TTM figure through Mar 2026 stood at $36.0 million (up 19.39% YoY), while the FY2025 annual figure was $27.4 million, down 8.38% from the prior year.
• Shares Outstanding (Entity) rose to $36.0 million in Q1 2026 per ANTX's latest filing, from $27.4 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $36.0 million in Q1 2026 and bottomed at $3.2 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $24.7 million across 5 years, with a median of $27.4 million in 2025.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 610.64% — and 2025, when it dropped 8.38%.
• AN2 Therapeutics' Shares Outstanding (Entity) stood at $15.3 million in 2022, then soared by 53.85% to $23.6 million in 2023, then climbed by 26.78% to $29.9 million in 2024, then declined by 8.38% to $27.4 million in 2025, then soared by 31.27% to $36.0 million in 2026.
• Business Quant data shows ANTX's Shares Outstanding (Entity) at $36.0 million in Q1 2026, $27.4 million in Q4 2025, and $27.4 million in Q3 2025.